Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy in breast cancer
Soley Bayraktar, Sameer Batoo, Scott H. Okuno, et al.
Journal of Carcinogenesis (2019) Vol. 18, Iss. 1, pp. 2-2
Open Access | Times Cited: 68

Showing 1-25 of 68 citing articles:

Tumor microenvironment components: Allies of cancer progression
Pablo Igor Ribeiro Franco, Arthur Perillo Rodrigues, Liliana Borges de Menezes, et al.
Pathology - Research and Practice (2019) Vol. 216, Iss. 1, pp. 152729-152729
Closed Access | Times Cited: 200
Ki-67 as a Prognostic Biomarker in Invasive Breast Cancer
Matthew G. Davey, Seán O. Hynes, Michael J. Kerin, et al.
Cancers (2021) Vol. 13, Iss. 17, pp. 4455-4455
Open Access | Times Cited: 175
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond
Alessandro Rizzo, Angela Dalia Ricci
Expert Opinion on Investigational Drugs (2021) Vol. 31, Iss. 6, pp. 549-555
Closed Access | Times Cited: 114
Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival
Lei Tu, Renguo Guan, Hanting Yang, et al.
International Journal of Cancer (2019) Vol. 147, Iss. 2, pp. 423-439
Open Access | Times Cited: 141
Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors
Kuo‐Ching Mei, Yu‐Pei Liao, Jinhong Jiang, et al.
ACS Nano (2020) Vol. 14, Iss. 10, pp. 13343-13366
Open Access | Times Cited: 132
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
Stefania Cocco, Michela Piezzo, Alessandra Calabrese, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 13, pp. 4579-4579
Open Access | Times Cited: 96
Aberrant hyperexpression of the RNA binding protein FMRP in tumors mediates immune evasion
Qiqun Zeng, Sadegh Saghafinia, Agnieszka Chryplewicz, et al.
Science (2022) Vol. 378, Iss. 6621
Closed Access | Times Cited: 57
Extensive review on breast cancer its etiology, progression, prognostic markers, and treatment
Harshini Swaminathan, K. Saravanamurali, Sangilimuthu Alagar Yadav
Medical Oncology (2023) Vol. 40, Iss. 8
Closed Access | Times Cited: 32
Pregnancy-Associated Breast Cancer: A Diagnostic and Therapeutic Challenge
Francesca Galati, Valentina Magri, Paula Andrea Arias-Cadena, et al.
Diagnostics (2023) Vol. 13, Iss. 4, pp. 604-604
Open Access | Times Cited: 23
Understanding Breast cancer: from conventional therapies to repurposed drugs
Bárbara Costa, Irina Amorim, Fátima Gärtner, et al.
European Journal of Pharmaceutical Sciences (2020) Vol. 151, pp. 105401-105401
Closed Access | Times Cited: 68
LncRNA GNAS-AS1 facilitates ER+ breast cancer cells progression by promoting M2 macrophage polarization via regulating miR-433-3p/GATA3 axis
Shiqin Liu, Zhiyang Zhou, Xue Dong, et al.
Bioscience Reports (2020) Vol. 40, Iss. 7
Open Access | Times Cited: 51
Interleukin-1 and Nuclear Factor Kappa B Signaling Promote Breast Cancer Progression and Treatment Resistance
Sydney Diep, Mahita Maddukuri, Stephanie Yamauchi, et al.
Cells (2022) Vol. 11, Iss. 10, pp. 1673-1673
Open Access | Times Cited: 34
Netrin-1 blockade inhibits tumor associated Myeloid-derived suppressor cells, cancer stemness and alleviates resistance to chemotherapy and immune checkpoint inhibitor
Benjamin Ducarouge, Anna Rita Redavid, Camille Victoor, et al.
Cell Death and Differentiation (2023) Vol. 30, Iss. 10, pp. 2201-2212
Open Access | Times Cited: 19
Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies
Rachel SJ Wong, Rebecca JM Ong, Joline SJ Lim
Cancer Drug Resistance (2023) Vol. 6, Iss. 4, pp. 768-87
Open Access | Times Cited: 16
Recent Progress on Immunotherapy for Breast Cancer: Tumor Microenvironment, Nanotechnology and More
Li Yang, Wenfang Miao, Doudou He, et al.
Frontiers in Bioengineering and Biotechnology (2021) Vol. 9
Open Access | Times Cited: 38
Targeted Inhibition of Anti-Inflammatory Regulator Nrf2 Results in Breast Cancer Retardation In Vitro and In Vivo
Venugopal R. Bovilla, Mahadevaswamy G. Kuruburu, Vidya G. Bettada, et al.
Biomedicines (2021) Vol. 9, Iss. 9, pp. 1119-1119
Open Access | Times Cited: 33
Chimeric antigen receptor T-cell immunotherapy in breast cancer: development and challenges
Sara Toulouie, Gary L. Johanning, Yihui Shi
Journal of Cancer (2021) Vol. 12, Iss. 4, pp. 1212-1219
Open Access | Times Cited: 28
Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer
Jakub Wesolowski, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak
Cancers (2022) Vol. 14, Iss. 16, pp. 3860-3860
Open Access | Times Cited: 21
Biomarkers related to immune checkpoint inhibitors therapy
Na Li, Xin Hou, Shaogang Huang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 147, pp. 112470-112470
Open Access | Times Cited: 20
Recent update on multi-epitope vaccine development for treating breast cancer
Z. Nafiah, A. Atha, A.I. Rizkita, et al.
Vacunas (2025), pp. 500390-500390
Closed Access
Breast Cancer during Pregnancy—Current Paradigms, Paths to Explore
Ayelet Alfasi, Irit Ben‐Aharon
Cancers (2019) Vol. 11, Iss. 11, pp. 1669-1669
Open Access | Times Cited: 35
Crosstalk between Tumor-Infiltrating Immune Cells and Cancer-Associated Fibroblasts in Tumor Growth and Immunosuppression of Breast Cancer
Jarupa Soongsathitanon, Pranisa Jamjuntra, Nuttavut Sumransub, et al.
Journal of Immunology Research (2021) Vol. 2021, pp. 1-15
Open Access | Times Cited: 24
An optimised patient-derived explant platform for breast cancer reflects clinical responses to chemotherapy and antibody-directed therapy
Constantinos Demetriou, Naila Abid, Michael Butterworth, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Interleukin‐37 improves T‐cell‐mediated immunity and chimeric antigen receptor T‐cell therapy in aged backgrounds
Jamie A.G. Hamilton, Miyoung Lee, Rae Hunter, et al.
Aging Cell (2021) Vol. 20, Iss. 2
Open Access | Times Cited: 21
Design of a Novel Recombinant Multi-Epitope Vaccine against Triple-Negative Breast Cancer
Hassan Dariushnejad, Vajihe Ghorbanzadeh, Soheila Akbari, et al.
PubMed (2022) Vol. 26, Iss. 2, pp. 160-74
Closed Access | Times Cited: 11
Page 1 - Next Page

Scroll to top